AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2023
Jul 25, 2023
35172_dirs_2023-07-24_c567d941-9fac-43d6-b19b-e83ae8277bec.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2023-06-27
Reporting Person: Neal James R (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-27 | Common Stock | M | 14407 | — | Acquired | 14407 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-27 | Restricted Stock | $0 | M | 14407 | Disposed | Common Stock (14407) | Direct | |
| 2023-06-27 | Restricted Stock | $0 | A | 101365 | Acquired | Common Stock (101365) | Direct |
Footnotes
F1: Vesting of time-based restricted shares.
F2: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders.
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15